USA - NYSE:TFX - US8793691069 - Common Stock
The current stock price of TFX is 124.47 USD. In the past month the price decreased by -4.91%. In the past year, price decreased by -41.07%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| DXCM | DEXCOM INC | 31.3 | 22.83B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B |
Teleflex, Inc. engages in the provision of medical technology products. The company is headquartered in Wayne, Pennsylvania and currently employs 14,100 full-time employees. The firm offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
TELEFLEX INC
550 E Swedesford Rd, Suite 400
Wayne PENNSYLVANIA 19087 US
CEO: Liam J. Kelly
Employees: 14100
Phone: 16102256800
Teleflex, Inc. engages in the provision of medical technology products. The company is headquartered in Wayne, Pennsylvania and currently employs 14,100 full-time employees. The firm offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
The current stock price of TFX is 124.47 USD. The price decreased by -0.3% in the last trading session.
TELEFLEX INC (TFX) has a dividend yield of 1.03%. The yearly dividend amount is currently 1.36.
TFX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
TELEFLEX INC (TFX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
The PE ratio for TELEFLEX INC (TFX) is 8.88. This is based on the reported non-GAAP earnings per share of 14.02 and the current share price of 124.47 USD.
The next ex-dividend date for TELEFLEX INC (TFX) is August 15, 2025.
ChartMill assigns a technical rating of 2 / 10 to TFX. When comparing the yearly performance of all stocks, TFX is a bad performer in the overall market: 86.65% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to TFX. TFX scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months TFX reported a non-GAAP Earnings per Share(EPS) of 14.02. The EPS increased by 2.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.31% | ||
| ROA | 2.6% | ||
| ROE | 4.52% | ||
| Debt/Equity | 0.42 |
21 analysts have analysed TFX and the average price target is 142.6 USD. This implies a price increase of 14.56% is expected in the next year compared to the current price of 124.47.
For the next year, analysts expect an EPS growth of 1.17% and a revenue growth 8.2% for TFX